Intrapulmonary pharmacokinetics of antibacterial agents: Implications for therapeutics

American Journal of Respiratory Medicine

Volumn 1, Issue 3, 2002, Pages 201-209

  Chiu, Loretta M ^a   Amsden, Guy W ^a  

^a BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEFPODOXIME PROXETIL; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; TROVAFLOXACIN; VANCOMYCIN;

ACCURACY; AREA UNDER THE CURVE; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; HUMAN; LUNG ALVEOLUS CELL; LUNG INFECTION; LUNG INTERSTITIUM; MEDICAL DECISION MAKING; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PHAGOCYTE; PHARMACODYNAMICS; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SAMPLING; TISSUE HOMOGENATE;

EID: 0038710351     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256610     Document Type: Review

References (43)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
2. Pennington JE. Penetration of antibiotics into respiratory secretions. Rev Infect Dis 1981; 3: 67-73
3. Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 1981; 8: 171-4
4. Saggers BA, Lawson D. Some observations on the penetration of antibiotics through mucus in vitro. J Clin Pathol 1966; 19: 313-7
5. Saggers BA, Lawson D. In vivo penetration of antibiotics into sputum in cystic fibrosis. Arch Dis Child 1968; 43: 404-9
6. Valcke Y, Pauwies R, Van Der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur Respir J 1990; 3: 715-22
7. Biagi GL, Guerra MC, Barbaro AM, et al. Influence of lipophilic character on the antibacterial activity of cephalosporins and penicillins. J Med Chem 1970; 13: 511-6
8. Barza M, Cuchural G. General principles of antibiotic tissue penetration. J Antimicrob Chemother 1985; 15 Suppl A: 59-75
9. Ogren S, Cars O. Importance of drug-protein interactions and protein concentrations for antibiotic levels in serum and tissue fluid. Scand J Infect Dis 1985; Suppl. 44: 34-40
10. Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? Rev Infect Dis 1987; 9 (4): 713-8
11. Ryan DM, Cars O, Hoffstedt B. The use of antibiotic serum levels to predict concentrations in tissues. Scand J Infect Dis 1986; 18: 381-8
12. Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30: 249-60
13. Cohen GM. Pulmonary metabolism of foreign compounds: its role in metabolic activation. Environ Health Perspect 1990; 85: 31-41
14. Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12: 631-46
15. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36: 1176-80
16. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992; 36: 1171-5
17. Cook PJ, Andrews JM, Woodcock J, et al. Concentration of amoxicillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 1994; 49: 1134-8
18. Amsden GW, Ballow CH, Forrest A. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin Drug Invest 1997; 13: 152-61
19. Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41: 1399-402
20. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375-9
21. Rodvold KA, Danziger LH. Intrapulmonary concentrations of clarithromycin and azithromycin: impact of differences in methodology on the variability of results [abstract]. Proceedings of the Sixth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; 2002 Jan 23-25; Bologna, 129. Atlanta (GA): Wallace Communications Inc., 2002
22. Ramphal R, Lhermitte M, Filliat M, et al. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 1988; 22: 483-90
23. Muller-Serieys C, Bancal C, Dombret MC, et al. Penetration of cepodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. Antimicrob Agents Chemother 1992; 36: 2099-103
24. Baldwin DR, Andrews JM, Ashby JP, et al. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax 1990; 45: 401-2
25. Nix DE, Goodwin D, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 1991; 35: 1953-9
26. Muller-Siereys C, Bergogne-Berezin E, Rowan C, et al. Imipenem penetration into bronchial secretions. J Antimicrob Chemother 1987; 20: 618-9
27. Marlin GE, Burgess KR, Burgoyne J, et al. Penetration of piperacillin into bronchial mucosa and sputum. Thorax 1981; 36: 774-80
28. Mazzei T, Novelli A, De Lalla F, et al. Tissue penetration and pulmonary disposition of tobramycin. J Chemother 1995; 7: 363-70
29. Carcas AJ, Garcia-Satue JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999; 65: 245-50
30. Lamer C, De Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37: 281-6
31. Yao JDC, Moellering RC. Antimicrobial agents: glycopeptides and lipopeptides. In: Balows A, Hausler WJ, Herrmann KL, et al., editors. Manual of clinical microbiology. 5th ed. Washington, DC: American Society for Microbiology, 1991: 1076-7
32. Freeman CD, Nightingale CH, Nicolau DP, et al. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob Agents Chemother 1994; 38: 2449-51
33. Baldwin DR, Wise R, Andrews JM, et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3: 886-90
34. Olsen KM, San Pedro GS, Gann LP, et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40: 2582-5
35. Honeybourne D, Kees F, Andrews JM, et al. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur Respir J 1994; 7: 1275-80
36. Decre D, Bergogne-Berezin E. Pharmacokinetics of quinolones with special reference to the respiratory tree. J Antimicrob Chemother 1993; 31: 331-43
37. Honeybourne D, Andrews JM, Ashby JP, et al. Evaluation of the penetration of ciprofloxacin and amoxicillin into the bronchial mucosa. Thorax 1988; 43: 715-9
38. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119: 1114-22
39. Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administrations of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 39: 797-802
40. Amsden GW. Pneumococcal macrolide resistance: myth or reality? J Antimicrob Chemother 1999; 44: 1-6
41. Kashuba ADM, Bertino Jr JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms. Antimicrob Agents Chemother 1998; 42: 1842-4
42. Amsden GW, Graci DM, Cabelus LJ, et al. A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. Chest 1999; 116: 115-9
43. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 811-8